Skip to main content

Table 4 Comparison of clinical parameters between JAK2-V617F mutant and wild type in three groups of patients

From: Retrospective analysis of the clinical features of 172 patients with BCR-ABL1-negative chronic myeloproliferative neoplasms

IndexPMFPPVPETP
M(n = 15)W*(n = 9)M(n = 73)W(n = 7)M(n = 47)W(n = 21)
Media age(y)69(42–78)58(47–70)0.12258(22–78)49(21–74)0.82159(28–81)58(18–85)0.532
Sex
 Male890.027*4260.23623120.605
 Female70 301 249 
WBC(109/L)7.5(2.7–23.1)20.7(1.3–51.8)0.49712.6(4.3–50.3)6.8(4.4–12.7)0.006*12.5(6–61)8(5.3–26)0.001*
Hb(g/L)90.7 ± 29.187.1 ± 46.00.303193.7 ± 19.8207.4 ± 29.60.089144.1 ± 24.3121 ± 25.60.001*
PLT(109/L)147(62–617)192(1–806)0.61404(93–1328)217(93–305)0.001*813.5(538–2240)985(416–2243)0.037*
Splenomegaly159/5530.045*2030.023*
Thrombosis110.621210.859930.742
Bone fibrosis   200.657210.676
APTT extension970.3325850.6362840.002*
PT extension420.6012530.691400.168
Abnormal FIB1040.2621430.1611040.273
High D-Di960.5472020.6251590.383
High LDH159/5060.66825140.299
Karyotype analysis
 Normal1260.4996870.68545210.475
 Abnormal43 40 20 
  1. ※M = mutation
  2. *W=Wild